Bicara Therapeutics (NASDAQ:BCAX) Releases Quarterly Earnings Results, Misses Expectations By $1.14 EPS

Bicara Therapeutics (NASDAQ:BCAX) posted its quarterly earnings results on Tuesday. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14), Zacks reports.

Bicara Therapeutics Stock Up 1.1 %

BCAX traded up $0.25 during midday trading on Thursday, reaching $22.25. The company had a trading volume of 163,282 shares, compared to its average volume of 355,075. Bicara Therapeutics has a 12-month low of $18.33 and a 12-month high of $28.09. The business’s 50-day moving average price is $23.43.

Insider Buying and Selling

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, September 16th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the purchase, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This represents a 74.20 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder James E. Flynn bought 70,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the transaction, the insider now owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. This represents a 8.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on BCAX shares. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target on the stock. Morgan Stanley began coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective on the stock. Stifel Nicolaus started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price for the company. TD Cowen began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Finally, RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Bicara Therapeutics currently has an average rating of “Buy” and an average price target of $43.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.